{"version":"1.0","provider_name":"Neuraxpharm SE","provider_url":"https:\/\/www.neuraxpharm.com\/se","author_name":"imones","author_url":"https:\/\/www.neuraxpharm.com\/se\/author\/imones\/","title":"Neuraxpharm announces closing of its acquisition by a company backed by funds advised by Permira","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"8jHubgjZWf\"><a href=\"https:\/\/www.neuraxpharm.com\/se\/media\/closing-acquisition-funds-advised-permira\/\">Neuraxpharm announces closing of its acquisition by a company backed by funds advised by Permira<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.neuraxpharm.com\/se\/media\/closing-acquisition-funds-advised-permira\/embed\/#?secret=8jHubgjZWf\" width=\"600\" height=\"338\" title=\"\u201dNeuraxpharm announces closing of its acquisition by a company backed by funds advised by Permira\u201d &ndash; Neuraxpharm SE\" data-secret=\"8jHubgjZWf\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.neuraxpharm.com\/se\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.neuraxpharm.com\/se\/wp-content\/uploads\/sites\/29\/2021\/03\/contact-header.jpg","thumbnail_width":1440,"thumbnail_height":445,"description":"Dr. J\u00f6rg-Thomas Dierks, CEO of Neuraxpharm, commented:\u00a0\u201cAs we look ahead to the next chapter in Neuraxpharm\u2019s development, the management team would like to thank Apax Partners for its support and confidence in our business over the last four years. A strong geographical expansion and a significant investment in our product pipeline have allowed to create a pan-European platform to support rapid and sustainable growth. We are now delighted to be supported by Permira, a strongly established growth investor, as we continue our journey to further grow and strengthen our position as a leading CNS specialist.\u201d"}